Biologic Makers Thwart Generics: Winning Stocks YCharts Hospira (HSP) and Teva halted late-stage development of follow-on versions of Roche AG's monoclonal antibody Rituxan (rituximab) -- $3.1 billion in domestic sales, trailing 12-months – due to rising R&D costs. Similar to strategies used to delay entry ... |
